Infinity: Jumps on fast track tag for breast cancer treatment

Infinity Pharmaceuticals

29/09/2020 13:41

** Drugmaker's shares  INFI.O  rise 26.55% to $1.43
premarket
    ** U.S. FDA grants fast track designation for co's breast
cancer treatment, eganelisib (IPI-549)  urn:newsml:reuters.com:*:nBw2PkjnRa
    ** Eganelisib to be used in combination with standard set of
therapies, including chemotherapy, as a first-line treatment for
inoperable metastatic triple-negative breast cancer - company
    ** Co is currently enrolling patients in an ongoing
mid-stage study with Roche/Genentech to evaluate eganelisib in
combination with two other drugs, Tecentriq and Abraxane
    ** The fast track tag speeds up the review process of drugs
to treat serious conditions         
    ** INFI stock up ~17% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))